CTIC - CTI BioPharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

CTI BioPharma Corp.

3101 Western Avenue
Suite 800
Seattle, WA 98121
United States
206-282-7100
http://www.ctibiopharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees58

Key Executives

NameTitlePayExercisedYear Born
Dr. Jack W. SingerCo-Founder, Exec. VP, Chief Scientific Officer, Interim CMO & Global Head-Translational Medicine522.99kN/A1943
Mr. Bruce J. SeeleyCOO, Exec. VP & Sec.503.35kN/A1964
Dr. Adam R. CraigPres, CEO & DirectorN/AN/A1966
Mr. David H. KirskeExec. VP & CFON/AN/A1954
Mr. Ed BellSr. Director of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. The company's product candidate in pipeline includes tosedostat, a novel oral, once-daily aminopeptidase inhibitor for patients with acute myeloid leukemia. It has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; Teva Pharmaceutical Industries Ltd; University of Vermont; S*BIO Pte Ltd; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Corporate Governance

CTI BioPharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.